Table 1.
Pathways common to Gene set enrichment analysis (GSEA) of the clinical genelist and pathway analysis of in vitro and clinical genelists. Pathways identified by pathway analysis contained ≥5 genes with a 1.5 fold-change and P<0.05. Only pathways identified from ≥4 genelists are listed.
| PATHWAY | PATHWAY ANALYSIS | GSEA | ||||||
|---|---|---|---|---|---|---|---|---|
| 5-FU in vitro |
Oxaliplatin in vitro |
Clinical 5FU/OXA |
Clinical 5FU/OXA |
|||||
|
Inducible
Parental |
Constitutively
Altered |
Inducible
Resistant |
Inducible
Parental |
Constitutively
Altered |
Inducible
Resistant |
R v NR | R v NR | |
| Adherens Junction | 6 | 13 | 8 | 12 | ||||
| Apoptosis | 7 | 5 | 7 | 8 | 5 |
|
||
| Axon guidance | 14 | 11 | 8 | 13 | ||||
| Calcium signalling | 8 | 9 | 7 | 9 | 8 | 10 |
|
|
| Cell communication | 5 | 6 | 5 | 14 |
|
|||
| Cell cycle | 21 | 11 | 13 | 8 | 14 | 14 |
|
|
| Cytokine-cytokine receptor interaction |
5 | 9 | 6 | 6 | 17 |
|
||
| Focal adhesion | 16 | 10 | 13 | 12 | 11 | 19 |
|
|
| Gap junction | 5 | 7 | 6 | 6 |
|
|||
| Glycerophospholipid metabolism |
8 | 6 | 6 | 7 |
|
|||
| Insulin signalling | 20 | 8 | 12 | 7 | 5 | 5 | 9 |
|
| MAPK signalling | 19 | 12 | 14 | 18 | 6 | 17 |
|
|
| Purine metabolism | 23 | 17 | 12 | 10 | 20 | 17 | ||
| Pyrimidine metabolism |
19 | 10 | 12 | 5 | 21 | 15 | ||
| Regulation of Actin cytoskeleton |
15 | 8 | 16 | 14 | 5 | 22 |
|
|
| Tight Junction | 6 | 7 | 14 | 12 | 14 | |||
| Wnt signalling | 12 | 8 | 8 | 5 | 8 | 10 | ||